Dashboard
Poor long term growth as Net Sales has grown by an annual rate of 1.09% and Operating profit at 5.85% over the last 5 years
Flat results in Sep 26
Stock is technically in a Bearish range
With ROE of 18.2, it has a Expensive valuation with a 4 Price to Book Value
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
INR 17,496 Cr (Small Cap)
22.00
40
1.95%
-0.68
18.19%
4.01
Total Returns (Price + Dividend) 
Latest dividend: 75 per share ex-dividend date: Jul-17-2026
Risk Adjusted Returns v/s 
Returns Beta
News

Pfizer Ltd. Reports Flat Quarterly Financial Trend Despite Record Sales and Profitability
Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has reported its September 2026 quarter results, marking record highs in net sales, profitability, and earnings per share. However, despite these impressive figures, the company’s overall financial trend has shifted from positive to flat, signalling a cautious outlook amid broader market challenges and relative underperformance against benchmarks.
Read More
Pfizer Ltd. is Rated Sell by MarketsMOJO
Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read More
Pfizer Ltd. is Rated Sell by MarketsMOJO
Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 31 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More Announcements 
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026.
03-Nov-2026 | Source : BSEPlease find enclosed unaudited financial results for the quarter and half year ended September 30 2026 along with the limited review report.
Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026.
26-Oct-2026 | Source : BSEPfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday November 3 2026 to consider approve and take on record the unaudited financial results for the quarter and half year ended September 30 2026.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
09-Oct-2026 | Source : BSEPlease find attached Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2026.
Corporate Actions 
No Upcoming Board Meetings
Pfizer Ltd. has declared 750% dividend, ex-date: 17 Jul 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 20 Schemes (12.83%)
Held by 87 FIIs (1.63%)
Pfizer East India B V (39.75%)
Nippon Life India Trustee Ltd (4.11%)
12.2%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 11.28% vs 3.80% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 53.20% vs 2.33% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 8.16% vs 4.06% in Sep 2024
Growth in half year ended Sep 2025 is 23.20% vs 27.45% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 11.90% vs 2.61% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 19.68% vs 17.23% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 10.45% vs 4.02% in Mar 2025
YoY Growth in year ended Mar 2026 is -5.88% vs 39.23% in Mar 2025